Comparing In-Vitro Effects of Two Immunosuppressive Drugs on the Expression of Foxp3 from Naïve CD4+ T Cells

Document Type : Original Article (s)

Authors

1 MSc Student, Department of Immunology, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Cellular and Molecular Immunology Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 PhD Student, Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Many studies showed that regulatory T cells (Tregs) have immunosuppressive effects on immune responses in transplantation and autoimmune disease. Silymarin (isolated from milk thistle or silybum marianum plant) is a flavolignan complex with anti-inflammatory, hepatoprotective, antioxidant and immunomodulatory activities. Previous studies in our group revealed inhibition effect of silymarin on mammalian target of rapamycin (mTOR) activity in activated T cells. Among immunosuppressive drugs, rapamycin can inhibit mTOR, results in Foxp3 expression, Tregs expansion and conventional T cells inhibition. In this study, the effect of silymarin on in-vitro generation of CD4+Foxp3+ cells, in comparison with rapamycin, was evaluated.Methods: Naïve CD4+ T cells were separated from healthy individuals’ peripheral blood mononuclear cells (PBMCs) and activated with monoclonal antibody anti-CD3 and anti-CD28 for 18 hours in Roswell Park Memorial Institute (RPMI) complete medium. Then, incubation was continued with adding Interlukin-2 (IL-2) and silymarin or its control, dimethyl sulfoxide (DMSO), or cultured in present or absent of rapamycin for 3 days. Cells were harvested and stained with anti-CD4 and anti-FoxP3 antibodies for flow cytometry.Findings: Silymarin increased CD4+Foxp3+ T cells compared with its control, DMSO, and with rapamycin after three days of culture of naïve T cells (P <0.05); while, rapamycin compared to its control (RPMI medium) did not increased CD4+Foxp3+ T cells during three days culture (P > 0.05).Conclusion: Given the importance of replacement less harmful medicine and Tregs role in regulating immune system, silymarin, as aTreg generation drug, can be used in the treatment of autoimmune diseases and even in organ transplantation. 

Keywords

References

  1. Gazak R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem 2007; 14(3): 315-38.
  2. Gharagozloo M, Amirghofran Z. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J Cancer Res Clin Oncol 2007; 133(8): 525-32.
  3. Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di SM, Donato V, et al. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res 2010; 61(5): 405-9.
  4. Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, et al. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit 2002; 8(11): BR439-BR443.
  5. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59(13): 3128-33.
  6. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420(6915): 502-7.
  7. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002; 196(3): 401-6.
  8. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108(1): 390-9.
  9. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9(9): 1144-50.
  10. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510.
  11. Blaha P, Bigenzahn S, Koporc Z, Schmid M, Langer F, Selzer E, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101(7): 2886-93.
  12. Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res 1995; 1: 53-71.
  13. Bocian K, Borysowski J, Wierzbicki P, Wyzgal J, Klosowska D, Bialoszewska A, et al. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol Dial Transplant 2010; 25(3): 710-7.
  14. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18(3): 1007-18.
  15. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001; 194(12): 1711-9.
  16. Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J Immunol 2003; 170(10): 5075-81.
  17. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105(12): 4743-8.
  18. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9(5): 324-37.
  19. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008; 105(22): 7797-802.
  20. Gao W, Lu Y, El EB, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7(7): 1722-32.
  21. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111(1): 453-62.
  22. Walsh PT, Buckler JL, Zhang J, Gelman AE, Dalton NM, Taylor DK, et al. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest 2006; 116(9): 2521-31.
  23. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005; 201(2): 259-66.
  24. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180(9): 5794-8.
  25. Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009; 28(3): 313-24.
  26. Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Basic Clin Pharmacol Toxicol 2013; 112(4): 251-6.
  27. Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von BH. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 2006; 212: 163-9.
  28. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+. J Exp Med 2003; 198(12): 1875-86.
  29. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 2004; 101(13): 4572-7.
  30. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C. In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat Protoc 2007; 2(7): 1789-94.
  31. Long SA, Buckner JH. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun 2008; 30(4): 293-302.
  32. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006; 177(2): 944-9.
  33. Kopf H, de la Rosa GM, Howard OM, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007; 7(13): 1819-24.
  34. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, et al. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res 2000; 49(1): 20-6.
Journal of Isfahan Medical School
Volume 33, Issue 329 - Serial Number 329
March and April 2015
Pages 457-466

Files

History

  • Receive Date: 14 November 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics